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Between 2000 and 2050, the number of new cancer patients diagnosed annually is expected to double, with an accompanying
increase in treatment costs of more than $80 billion over just the next decade. Eﬃcacious strategies for cancer prevention
will therefore be vital for improving patients’ quality of life and reducing healthcare costs. Judah Folkman ﬁrst proposed
antiangiogenesis as a strategy for preventing dormant microtumors from progressing to invasive cancer. Although antiangiogenic
drugs are now available for many advanced malignancies (colorectal, lung, breast, kidney, liver, brain, thyroid, neuroendocrine,
multiple myeloma, myelodysplastic syndrome), cost and toxicity considerations preclude their broad use for cancer prevention.
Potent antiangiogenic molecules have now been identiﬁed in dietary sources, suggesting that a rationally designed antiangiogenic
diet could provide a safe, widely available, and novel strategy for preventing cancer. This paper presents the scientiﬁc,
epidemiologic, and clinical evidence supporting the role of an antiangiogenic diet for cancer prevention.
1.Introduction
Cancer now aﬀects as many as 24 million people worldwide,
and results in over six million deaths each year [1]. In the
United States, men and women have a 43% and 38% chance,
respectively, of being diagnosed with any type of cancer
during their lifetime [2]. Despite advances in the early detec-
tion of cancer, most malignancies are still diagnosed and
treatedatadvancedstages,withalimitedrangeoftherapeutic
options and poor overall survival. Simultaneously, cancer
treatment costs are escalating, from $125 billion annually in
theUSin2010toaprojected$207billionby2020[3].Cancer
prevention is, thus, a key opportunity for managing the
cancerpandemic.Unlikeinterventionalapproachesdelivered
to patients diagnosed with advanced cancer, preventative
strategies must be suitable for healthy individuals and have
low systemic toxicity, inhibiting microscopic tumor growth
with minimal adverse eﬀects on healthy tissues [4].
It is now well established that solid tumor growth is
dependent upon angiogenesis, the growth of new blood
vessels [5–10]. During early stages of tumorigenesis, the
induction of angiogenesis by cancer cells is a critical event
separating the preinvasive and dormant form of cancer from
the invasive and metastatic phases of malignant growth.
Multiple studies have demonstrated that the degree of
tumor vascularity correlates positively with disease stage,
the likelihood of metastases, and cancer recurrence [11, 12].
Angiogenesis also plays a role in hematogenous malignan-
cies, such as leukemia, lymphoma, and multiple myeloma,
as well as in premalignant myelodysplastic syndromes [13–
17]. In these pathologies, vascular endothelial cells sustain
and promote malignant cell growth by secreting paracrine
survival factors [18, 19].
Antiangiogenic therapy has been validated as an eﬀective
cancer treatment strategy for a growing number of cancer
types, including colorectal, renal, liver, lung, brain, pancre-
atic neuroendocrine tumors (NET), gastrointestinal stromal
tumors (GIST), multiple myeloma, and myelodysplastic
syndrome [20]. More than 120 novel antiangiogenic agents
are in clinical, trials [20–22] .I m p o r t a n t l y ,ag r o w i n gb o d y
of preclinical, clinical and epidemiological data is demon-
strating that angiogenesis inhibition can be applied for
achieving cancer prevention [23, 24]. This paper presents the
scientiﬁc and clinical evidence supporting antiangiogenesis
as a rational strategy for the prevention of cancer, exploiting
factors that are naturally present in dietary sources.
2.The PhysiologicalState of
Angiogenesis Regulation
The human body contains 60,000 miles of blood vessels,
including 19 billion capillaries. All normal cells in the body2 Journal of Oncology
are located no further than 100–200μm from the nearest
capillary, the diﬀusion limit of oxygen [25]. Capillaries not
only deliver oxygen and micronutrients to tissues, but the
endothelial cells comprising them secrete paracrine growth
and survival signals that inﬂuence adjacent nonvascular
cells [18]. Under physiological conditions, the rate of cell
proliferation is balanced with the rate of cell death (apop-
tosis), so there is no net tissue growth. Expansion of tissue
mass requires angiogenesis to support increased metabolic
demand [9]. In normal healthy adults, angiogenesis is
constitutively suppressed except for brief bursts during the
female reproductive cycle (endometrial regeneration, corpus
luteum formation), pregnancy (placentation), and wound
healing (granulation) [26–30]. The physiological state is thus
maintained in a constitutive state of suppressed angiogenesis
by endogenous inhibitory mechanisms opposing the action
of angiogenic growth and other stimulating factors.
2.1. Angiogenic Growth Factors. More than 30 endoge-
nous molecules have been identiﬁed as angiogenic factors
(Table 1).Thesesharetheabilitytostimulateneovasculariza-
tion in vivo and induce endothelial proliferation, migration,
or capillary tube formation in vitro. Basic ﬁbroblast growth
factor (bFGF or FGF2) was the ﬁrst angiogenic factor to
be identiﬁed from a tumor extract, but vascular endothelial
growth factor/vascular permeability factor (VEGF/VPF) is
the best studied [30]. VEGF is a potent endothelial mitogen
that increases vascular permeability, and also induces Bcl-
2, promoting vascular survival [31–34]. VEGF is expressed
by all human tumors studied and its receptors (VEGFR-1,
-R2, -R3 and -R4) are expressed selectively on angiogenic
endothelial cells [35]. Placental growth factor (PlGF) plays a
speciﬁc role in pathological neovascularization by recruiting
bone marrow-derived vascular stem cells to disease sites
[36, 37]. Other factors include platelet-derived growth
factor (PDGF), platelet-derived endothelial cell growth fac-
tor (PD-ECGF), interleukin-3 (IL-3), interleukin-8 (IL-8),
transforming growth factor-β (TGFβ), and tumor necrosis
factor-alpha (TNFα)[ 38, 39]. Other angiogenic factors are
neuregulin, a ligand for the ErbB receptor, and keratinocyte
growth factor (KGF or FGF-7) [40, 41]. Angiogenic factors
are observed at low levels or undetectable in the circulation
in normal, healthy subjects. By contrast, markedly elevated
levels of factors such as bFGF, VEGF, and PD-ECGF are
present in the serum, urine, and cerebrospinal ﬂuid of cancer
patients [42, 43].
2.2. Physiological Inhibition of Angiogenesis. Angiogenesis
inhibitory activity was ﬁrst discovered in studies of cartilage,
a naturally avascular tissue [44]. Numerous endogenous
antiangiogenic molecules have subsequently been iden-
tiﬁed, including troponin-1, tissue inhibitors of matrix
metalloproteinases (TIMPs), chondromodulin I, connective
tissue-growth factor (CTGF), decorin, metastatin, pigment
epithelium-derived factor (PEDF) thrombospondin-1 and
-2, interferons, tetrahydrocortisol-S, platelet factor-4, and
protamine [45–60]. Other inhibitors, such as canstatin, tum-
statin, and arresten, are present in the basement membrane
surrounding established blood vessels [61–63].
Table 1: Angiogenic factors.
Angiogenin
Angiopoietin-1
Adrenomedullin
Del-1
Fibroblast growth factor-1 (acidic FGF, FGF1)
Fibroblast growth factor-2 (basic FGF, FGF2)
Follistatin
Granulocyte-colony-stimulating factor (G-CSF)
Hepatocyte growth factor/scatter factor (HGF/SF)
Interleukin-3 (IL-3)
Interleukin-8 (IL-8)
Intermedin
Keratinocyte growth factor (FGF-7)
Leptin
Midkine
Neuregulin
Osteogenic protein-1
Placental growth factor (PlGF)
Platelet-derived endothelial-cell growth factor (PD-ECGF)
Platelet-derived growth factor (PDGF)
Pleiotrophin
Progranulin
Proliferin
Transforming growth factor-α (TGFα)
Transforming growth factor-β (TGFβ)
Tumor necrosis factor-α (TNFα)
Vascular endothelial growth factor/vascular permeability
factor (VEGF/VPF)
A separate and distinct class of inhibitors is com-
prised of proteolytic fragments derived from cleaved larger
molecules. Angiostatin is an internal fragment of plas-
minogen and speciﬁcally inhibits endothelial cell prolifer-
ation [64]. Enzymes such as macrophage-derived elastase
and serine proteases generate angiostatin or angiostatin-
like fragments [65, 66]. Endostatin, a 20-kDa fragment
of collagen XVIII, is a speciﬁc angiogenesis inhibitor that
induces endothelial apoptosis [67, 68]. Both angiostatin
and endostatin were discovered in the serum of tumor-
bearing experimental mice,suggestingthattumor-associated
protease activity generates these inhibitors. Removal of the
primary tumor led to a marked decline in serum angiostatin
and endostatin, followed by rapid angiogenic growth of
metastatic lesions [9, 69]. Endostatin is present at a low
circulating level in normal subjects [70]. Collectively, these
endogenous angiogenesis inhibitors play a dominant role in
suppressing angiogenesis in health and contribute to tumor
dormancy (Table 2).
2.3. Balance and Imbalance of Angiogenesis. Vascular growth
isphysiologicallygovernedbyahomeostaticbalancebetweenJournal of Oncology 3
Table 2: Endogenous inhibitors of angiogenesis.
Angiopoietin-2 (in the absence of VEGF)
Angiostatin
Antithrombin III fragment
Arresten
Canstatin
Chondromodulin I
Connective tissue growth factor (CTGF)
Decorin
Endorepellin
Endostatin
Fibronectin 20-kDa fragment
Interferons-α, β,a n dγ
Interleukin-4 (IL-4)
Interleukin-10 (IL-10)
Interleukin-12 (IL-12)
Interferon-inducible protein-10 (IP-10)
Kringle 5
Metastatin
METH-1
METH-2
2-Methoxyestradiol
Osteopontin cleavage product
PEX
Pigment epithelium-derived factor (PEDF)
Plasminogen activator inhibitor (PAI)
Platelet factor-4
Prolactin 16-KDa fragment
Proliferin-related protein
Prothrombin kringle 2
Maspin
Restin
Soluble fms-like tyrosine kinase-1 (S-Flt-1)
SPARC cleavage product
Tetrahydrocortisol-S
Tissue inhibitors of matrix metalloproteinases (TIMPs)
Thrombospondin-1 and -2
Transforming growth factor-β (TGF-β)( activated form)
Troponin-1
Tumstatin
Vascular endothelial growth inhibitor (VEGI)
Vasostatin
positiveandnegativeangiogenesisregulators,sothatneovas-
cularization is normally suppressed [71]. Vascular prolifer-
ation occurs when angiogenic growth factor production is
upregulated, or when expression of endogenous inhibitors
is downregulated, or when both events occur simultane-
ously [72–74]. The genetic regulators of angiogenesis are
closely related to tumor growth promotion and suppression
(Table 3). Gene knockout studies in mice have shown that
Table 3: Genetic control of angiogenesis.
Id1 p53
Id3 Rb
HIF-1a VHL
K-ras PTEN
N-myc trk B
c-myc p16INK4a
c-fos
c-src
c-myb
c-jun
HER2/neu
EGFT
Raf
Mek
p73
Del-1
FzD
Bcl2
MDNM2
PML-RAR
ElF-4E
Id1 and Id3, peptides that control cell diﬀerentiation by
interfering with DNA binding of transcription factors, are
required for normal vascular formation and induction of
angiogenesis in tumor-bearing animals [75]. The activated
forms of the oncogenes H-ras,v - raf,c - myc,c - src, Her-2/neu,
and p73 are associated with cellular production of VEGF
as well as tumorigenesis [76–83]. Several tumor-suppressor
genes regulate angiogenesis inhibition, including p53, Rb,
vHL, phosphatase and tensin homolog (PTEN), and trk B
[84] Wild-type p53 controls expression of the angiogenesis
inhibitor thrombospondin and decreases tumor neovascu-
larization; mutant p53 leads to the opposite eﬀect [73]. The
retinoblastoma (Rb) gene and the von Hippel-Lindau (vHL)
gene both downregulate VEGF expression; their mutation
leads to VEGF production, angiogenesis, and tumor growth
[85, 86].
2.4. The Avascular Dormant Phase of Cancer. Microscopic
cancer cells are commonly present in the healthy adult, the
result of errors during replication of 60–90 trillion cells. To
acquire sustenance, the incipient tumors (60–80 cells) may
migrate toward existing host vessels, a process known as
vessel cooption, but their growth remains limited [87–89].
Tumorsarecapableofgrowthtoapprox0.5mm3 indiameter
(10,000,000 cells) before reaching a steady state of growth.
Beyond this size, their metabolic demands exceed the supply
of oxygen and nutrients obtained by passive diﬀusion from
nearby blood vessels. This state corresponds to carcinoma in
situ, and the rate of tumor cell proliferation is balanced by
apoptosis [90]. Such microscopic tumors may exist for years
without clinical detection.4 Journal of Oncology
Figure 1: The switch to the angiogenic phenotype occurs during multistage tumorigenesis. As malignancy develops, cells progress from a
prevascularstage(normaltoearlyhyperplasia)toavascularstage(latehyperplasiatodysplasiatoinvasivecarcinoma).Angiogenesisbecomes
clearlyevidentduringdysplasiaandiscriticalforfurthergrowth.Targetingtumorangiogenesismaybeanovelstrategyforpreventingcancer.
(Reprinted by permission from the Angiogenesis Foundation. Copyright 2011 by The Angiogenesis Foundation. All rights reserved).
Autopsy studies have shown that these microscopic
cancers are present in the breasts of up to 40% of women
between the ages of 40 and 50 years, and in 50% of prostates
in men between 50 and 60 years. By age 70, microscopic can-
cers are detected in the thyroids of virtually everyone. Most
of these tumors never become clinically signiﬁcant, leading
to the concept of “cancer without disease” as a normal
state during aging. Physiological angiogenesis inhibition is
regarded as one of the mechanisms that prevent microscopic
cancers from converting to a malignant phenotype.
2.5. The “Switch” to the Angiogenic Phenotype during Mul-
tistep Tumorigenesis. To expand beyond the limits of the
preexisting vascular supply, tumors recruit new blood vessels
from surrounding vessels, an event known as the “switch”
to the angiogenic phenotype [91] (see Figure 1). Three
classic studies employing transgenic mice have delineated
this switch as normal cells undergo the transition from
normalcy to hyperplasia to dysplasia, and ﬁnally to frank
carcinoma.
In a model of spontaneous β-islet cell tumor formation,
Rip1-Tag2 transgenic mice selectively express the SV40 T-
antigen oncogene in their insulin producing β cells and
undergo a predictable sequence of multistep tumorigenesis
[71, 92, 93]. The transformed β-cells are localized to
approx 400 islets in the pancreas, of which 100% express
the oncogene. Over time, 50–70% of these islets become
hyperplastic nodules. A distinct angiogenic stage occurs at
6-7wk of age between the hyperplastic stage and the time
at which subset islets become invasive carcinomas at 12–16
weeks. The angiogenic capacity of these lesions is observed
as visible intense tumor vascularization, accompanied by
induction of capillary sprouting, endothelial proliferation,
and a starburst-like convergence of capillaries when islets are
harvested in vivo and cocultured with endothelial cells in
vitro. Importantly, nonangiogenic islets are unable to grow
beyond 0.6–0.8mm3 in size, whereas the small subset of
angiogenic islets can expand into a lethal tumor burden [94].
A second study utilized the bovine papillomavirus onco-
gene in a transgenic mouse model of dermal ﬁbrosarcoma
[95, 96]. Distinct stages of tumorigenesis are observed,
from normal cells to a proliferative hyperplastic stage (mild
and aggressive ﬁbromas) to neoplasia (ﬁbrosarcoma). The
preneoplastic ﬁbromas grow horizontally within the dermis
as thin avascular lesions, and the ﬁbrosarcomas are expansile
and densely vascularized. Angiogenesis is ﬁrst observed
during the late preneoplastic stage (aggressive ﬁbroma)
and sustained until death of the animals by ﬁbrosarcoma.
Aggressive ﬁbromas and ﬁbrosarcomas secrete bFGF. By
contrast, bFGF is not secreted by normal cells or by mild
ﬁbromas.
A third study involved K14-HPV16 transgenic mice in
which the human papillomavirus (HPV) type 16 oncogene
is targeted to expression in basal cells of the epidermis
by regulatory elements of the human keratin-14 promoter
[97]. These basal keratinocytes undergo sequential changes
from normal cells (no vascularization) to hyperplasia (mild
vascularization from the underlying dermis) to dysplasia
(abundant vessels under the basement membrane in close
apposition to aberrant keratinocytes) to squamous cell
carcinoma (intense angiogenesis breaching the basement
membrane into the tumor). In hyperplasia, dysplasia, and
at the invading cancer front, angiogenesis is associated with
mast cell inﬁltration and degranulation [98]. Mast cells
contain numerous angiogenic stimulators in their secretory
granules, such as the serine protease MCP-4, VEGF, bFGF,
TGFβ,TNFα,andIL-8[99,100].Indysplasiaandcarcinoma,
tissue expression of VEGF was increased, correlating to
increased tumor vessel density [101].
Together, these data demonstrate that angiogenesis is a
discrete, genetically regulated and rate-limiting step during
multisteptumorigenesis,thatthetransitionfromprevascular
to vascular phase is accompanied by the production and
release of one or more angiogenic growth factors, and that
host inﬂammatory cells may amplify the angiogenic switch
by contributing additional stimuli.
2.6. The Vascular Phase of Cancer. The onset of angiogenesis
precedes an exponential phase of tumor growth accompa-
nied by local organ invasion. The velocity of angiogenic
capillary growth ranges from 0.223 to 0.8mm/day [102–
104]. Studies of avascular tumor explants placed in the
anterior chamber of the eye show that once new vessels reach
the explant, tumors can expand 16,000-fold in size in 2wk
[105]. During this expansion, cancer cells grow as a cuﬀ
around each new microvessel with a thickness of 50–200μm.
In this conﬁguration, one endothelial cell supports the
metabolic needs of 5–100 cancer cells [106, 107]. Eventually,
invading blood vessels occupy 1.5% of the tumor volume
[108]. Tumor angiogenesis also facilitates cancer metastasesJournal of Oncology 5
Table 4: Approved antiangiogenic agents and cancer indications.
Bevacizumab (Genentech/Roche) Colon, Lung, Breast, Brain, Kidney
Cetuximab (Bristol-Myers Squibb/Imclone) Colon, Head and Neck
Endostatin (Simcere)† Lung
Erlotinib (Genentech/Roche/OSI) Lung, Pancreatic
Everolimus (Novartis) Kidney, Pancreatic/NET∗, Brain/SEGA∗∗
Imiquimod (Graceway/3M) Actinic keratosis, Basal cell carcinoma
Interferon alfa (Roche/Schering) Melanoma, Kaposi’s sarcoma
Lenalidomide (Celgene) Myleodysplastic syndrome, Multiple myeloma
Pazopanib (GlaxoSmithKline) Kidney
Sorafenib (Bayer/Onyx) Kidney, Liver
Sunitinib (Pﬁzer) Kidney, GIST, Pancreatic/NET∗
Temsirolimus (Wyeth) Kidney, Lymphoma
Thalidomide (Celgene) Multiple myeloma
Vandetanib (AstraZeneca) Thyroid
†Available only in China.
∗Neuroendocrine tumor.
∗∗Subependymal giant cell astrocytoma, associated with tuberous sclerosis.
Source: Angiotracker, The Angiogenesis Foundation (http://www.angio.org/).
byallowingcellstoexitthroughtheneovascularnetworkinto
the systemic circulation [109]. Elegant studies of mammary
carcinomas in mice have shown that a 1cm tumor sheds up
to 4 × 10 − 6 malignant cells into the circulation every 24h
[110].
3. Targeting Tumor Angiogenesis for
Cancer Prevention
The concept of “antiangiogenesis” was ﬁrst proposed in
1971 by Judah Folkman, who hypothesized that inhibition of
neovascularization at an early stage of cancer development
could prevent tumor growth and metastases and maintain
tumor dormancy [7]. A vast literature establishes that
angiogenesis inhibition is an eﬀective strategy to restrict
cancer growth in animal models bearing a wide variety
of cancers [8, 111]. To date, more than 300 angiogenesis-
inhibitory molecules have been identiﬁed as potential drug
candidates, including many natural and synthetic chemical
entities (reviewed in 55). Selective targeting of angiogenic
bloodvesselsispossibleasaresultofdiﬀerentialproliferation
rates between normal and tumor-associated endothelium.
The normal vasculature is highly quiescent, with only one
in every 10,000 endothelial cells dividing at any given time,
and a physiological doubling time ranging from 47 to 20,000
days [112–114]. In contrast, the doubling rate for tumor
endothelium is 2–13 days. Thus, antiangiogenic agents are
selectiveininhibitingproliferatingtumorvasculature,butdo
not aﬀect normal blood vessels.
3.1. Targets of Tumor Angiogenesis. Speciﬁc molecular and
cellular targets have been identiﬁed for tumor angiogenesis.
These include targets present during the orderly events char-
acterizing new blood vessel growth [115]. These include (1)
angiogenic growth factor production, release, and receptor
activation, (2) degradation of vascular basement membrane,
(3) endothelial proliferation, migration, and survival, (4)
bloodvesselsproutingandinvasion,(5)tubularmorphogen-
esis, (6) arterial-venous patterning, (7) vascular maturation,
and (8) recruitment of endothelial stem cells.
3.2. Clinical Principles of Antiangiogenic Therapy. The clin-
ical development of antiangiogenic therapy began in the
late 1980s. The ﬁrst successful treatment of a vascular
tumor (pulmonary hemangiomatosis) occurred in 1989
using interferon-α 2a as an antiendothelial agent [116]. The
ﬁrst drug to enter formal clinical trials as an angiogenesis
inhibitor was TNP-470 in 1992 [117]. Since 2004, more than
14 diﬀerent antiangiogenic agents have been demonstrated
to be eﬃcacious in treating solid and hematogenous cancers,
primarily in the setting of advanced disease (see Table 4).
To date, most agents that are speciﬁc or selective for
angiogenesis are well tolerated in humans, with fewer serious
(Grade 3 and 4) toxicities observed in their clinical trials
when compared to cytotoxic chemotherapy drugs [118–
120]. Because only proliferating endothelium is targeted, the
traditional side eﬀects of chemotherapy, such as leukopenia,
alopecia, and mucositis, are rarely observed. With some
antiangiogenic agents, a maximum tolerated dose (MTD)
cannot be determined [70]. This has led some clinical
investigations to incorporate pharmacodynamic techniques
for determining the optimal biological dose (OBD) of agents
in clinical trials.
Collectively, translational research studies have shown
that overall disease burden is important to consider in
the evaluation of the clinical eﬀects of any antiangiogenic
agent. Advanced cancers contain well-established, extensive
vascular networks that may respond minimally to angio-
genesis inhibitors. Vascular destructive agents, also known
as vascular targeting agents, may be required to achieve a
clinically signiﬁcant eﬀect on tumor perfusion [121–123].
Indeed, most preclinical studies of angiogenesis inhibitors6 Journal of Oncology
demonstrate drug eﬃcacy in the setting of incipient disease
(prevention) or small tumors (early intervention). Clinical
trials of the same agents, however, have often enrolled
patients with advanced, metastastic, and heavily pretreated
disease, perhaps explaining diﬀerences between mice studies
andtheresultsofhumantrials[124].Antiangiogenictherapy
in the adjuvant setting to suppress minimal residual disease,
or as an intervention for early-stage disease or cancer
prevention, has been proposed as the scenario of the greatest
clinical beneﬁt using angiogenesis inhibitors [125].
The remainder of this paper is devoted to discussing the
potentialforangiogenesisinhibitorsforpreventionofcancer.
4. Early Intervention and Cancer Prevention
4.1. Early Intervention. Angiogenesis inhibition oﬀers an
opportunity to interrupt an early, rate-limiting step in
tumorigenesis[126,127].Suppressionofpathologicalblood-
vessel growth prevents early tumors from progressing to
the malignant phenotype. Clinical correlates to preinvasive
angiogenic lesions are commonly encountered in breast
(ductal carcinoma in situ—DCIS), cervix (cervical intraep-
ithelial neoplasia—CIN), skin (actinic keratosis), orophar-
ynx (late Barrett’s esophagus), lung (squamous metaplasia
with dysplasia in bronchial mucosa), colon (premalignant
adenoma), and prostate (high-grade prostate intraepithelial
neoplasia, HGPIN) [128–133]. Microscopic metastases are
also present in many cancer patients who are undergoing
tumor resection with curative intent. For example, 25% of
colon cancer patients eventually develop hepatic metastases
after primary tumor resection emerging from preangiogenic
lesions that were present at the time of surgery [134–136]. By
suppressing tumor neovascularization at subclinical stages,
tumor progression and metastatic growth may be halted.
4.2. Superiority of Early Therapy and Sustained Angiogen-
esis Suppression. Animal studies have demonstrated that
early administration of angiogenesis inhibitors is highly
eﬃcacious. The drug TNP-470 (O-[chloroacetyl-carbonyl]
fumagillol)isapotentantiangiogenicanalogoftheantibiotic
fumagillin [124, 137]. A rat model of liver metastasis using
K12/TRb rat colon adenocarcinoma cells was employed to
study the diﬀerential eﬃcacy of early, early prolonged, or
delayedadministrationofTNP-470(15mg/kg)onmetastatic
burden and survival [134]. Treatment initiated at d1 after
tumor inoculation (early intervention) and maintained for
28d (prolonged therapy) led to a 46% reduction in liver
metastases and improved survival time compared to controls
(P = 0.011). Another study showed a superior reduction in
metastases with early (d 0–6) compared to delayed (d 7–13)
TNP-470 treatment in rabbits bearing VX2 carcinoma [138].
The eﬀect of TNP-470 on subclinical disease has also
been elegantly studied by Shusterman and colleagues [139].
In the ﬁrst study, xenografts of human neuroblastoma-
derivedCHP-134wereimplantedintoathymic(nu/nu)mice,
with initiation of antiangiogenic treatment 12h following
grafting (early primary tumor model). Treated tumors were
reduced by 90%, compared to control animals. The second
study involved administration of TNP-470 12h following
Table 5: Chemopreventive agents that possess antiangiogenic
properties.
Alpha-diﬂuoromethylornithine (DFMO)
Aspirin
Brassinin
Celecoxib
Curcumin
1 α,25-dihydroxyvitamin D3
Ellagic acid
Epigallocatechin 3-gallate
Finisteride
Genistein
N-acetylcysteine (NAC)
Naringenin
Oltipraz
Resveratrol
Retinoids
Selenium
Silymarin
Statins
Sulindac
Tamoxifen
Source: Angiotracker, The Angiogenesis Foundation
(http://www.angio.org/).
tail vein injection of CHP-134 cells into SCID/Beige mice
(metastatic model). Autopsy of saline-treated control mice
showed neuroblastoma deposits in the kidney, liver, adrenal
gland, and ovaries in 75% of subjects, whereas TNP-470-
treated mice showed no evidence of metastases. A third
study evaluated TNP-470 eﬀects in mice whose tumors
were initially 0.35mm3, but then became diﬃcult to palpate
following 10d of cyclophosphamide treatment (minimal
residual disease model). TNP-470 was then administered
subcutaneously. Tumor growth was suppressed in the TNP-
470-treated group by 82%, compared to saline-treated
controls. Histopathological analyses showed increased apop-
tosis by TdT-mediated nick-end labeling (TUNEL) assay
in treated animals, but no with diﬀerence in tumor cell
proliferation by Ki-67 assessment [90, 139]. These data
demonstrate the importance of timing in antiangiogenic
therapy and its eﬃcacy in subclinical disease.
4.3. Evidence for Antiangiogenic Cancer Prevention. Cancer
chemoprevention is deﬁned as the use of pharmacological,
natural, or dietary agents to inhibit the development of inva-
sive cancer by blocking DNA damage caused by carcinogens
or by arresting the progression of premalignant cells after
damage has already occurred [4]. Angiogenesis inhibition
blocks carcinogenesis by preventing progression to the
invasivephenotype[111,140,141].Anumberofwell-known
chemopreventive agents have antiangiogenic properties in
vivo and in vitro (see Table 5). These include retinoids, vita-
min D3, tamoxifen, oltipraz, curcumin, linoleic acid, ellagicJournal of Oncology 7
acid, selenium, α-diﬂuoromethylornithine (DFMO), N-
acetyl-l-cysteine (NAC), catechins, and celecoxib [142–151].
Classical angiogenesis assay systems, such as the chorioallan-
toic membrane assay (CAM), the corneal micropocket assay,
and modiﬁed rat aortic ring assay, have been used to screen
for biological activity of established chemopreventive agents
[152,153].Knownangiogenesisinhibitorssuchasendostatin
have also been shown to suppress carcinogen-induced tumor
development in rodent models [154]. The antiangiogenic
properties of select chemopreventive molecules shall be
discussed.
4.4. Antiangiogenic Factors in Dietary Sources
4.4.1. Green Tea Catechins. After water, tea is the second
most popular liquid in the world, and its consumption
is linked with a decreased risk of colon, prostate, lung,
esophageal, and other cancers [155–157]. Laboratory studies
have demonstrated that green tea and its catechins prevent
mutagenesis, tumorigenesis, cancer invasion and metas-
tases, and angiogenesis [158–163]. Polyphenol catechins in
tea, predominantly ﬂavanols, possess chemopreventive and
antiangiogenicactivity.Epigallocatechin-3-gallate(EGCG)is
a potent tea ﬂavonoid that speciﬁcally inhibits endothelial
cell proliferation stimulated by bFGF and induces avascular
zones in the chick CAM assay. Mice that consume 1.25%
green tea (human equivalent of drinking 2-3 cups of tea/day)
show inhibition of VEGF-stimulated corneal neovascular-
ization by as much as 70% and reduction of tumor cell
invasion by 50% [163]. Green tea solution 0.6% adminis-
tered to mice as the sole source of drinking ﬂuid results
in less tissue VEGF expression seen by immunostaining
and lower microvessel density in lung adenomas, as well as
signiﬁcantly fewer tumors induced by the NNK carcinogen
[162].
The molecular mechanism of EGCG is the result of its
inhibition of urokinase and two gelatinases (MMP-2 and -9)
involvedinvascularaswellastumorinvasion[164,165].The
MMP inhibitory activity is independent of zinc or calcium
binding by EGCG. High doses of EGCG induce apoptosis
when topically applied to SKH-1 hairless mice bearing UVB-
induced squamous cell carcinomas [166]. Clinical trials
are underway in Western and Asian nations to study the
chemopreventive potential of green tea for oral, prostate,
skin, and other cancers.
Preliminarydatafromthesetrialssuggestclinicaleﬃcacy.
An Italian study involving men with high-grade prostate
intraepithelialneoplasia(HGPIN)demonstratedaprotective
eﬀect from consuming daily green tea catechins over the
course of a single year [167]. The double-blind, placebo-
control study randomized sixty men with HGPIN into
a treatment arm receiving 600mg of puriﬁed green tea
catechins (equivalent to 2-3 cups of tea/day) and a placebo
arm.Themenwerefollowedforoneyear,atwhichpointthey
underwent prostate mapping via core needle biopsies. Based
on those biopsy results, 30% of the placebo group progressed
to prostate cancer, while the treatment arm demonstrated
an impressively low progression rate of 3%. Similarly,
a Japanese interventional study of patients with recently
removed colonic adenomas demonstrated that participants
drinking an average of 12 cups equivalent of green tea
polyphenols, obtained through both puriﬁed extracts and
w h o l et e a ,h a da5 0 %r e d u c t i o ni nr i s ko fa d e n o m ar e c u r -
rence compared to patients who drank an average of six cups
of green tea [168]. Chemopreventive eﬀects in humans have
also been observed through experimental trials involving
the treatment of precancerous oral and cervical lesions
[169, 170].
P o l y p h e n o nE ,a ne x t r a c tf r o mg r e e nt e al e a v e sc o n -
taining a deﬁned mixture of polyphenolic catechins, is in
clinical trials for prostate, bladder, esophageal, lung, head
andneckcancers,andleukemia.Intopicalform,Polyphenon
E 15% ointment was approved by the U.S. FDA in 2006 as
a treatment for external genital warts, which is considered
an angiogenic neoplasm and a precursor to cervical cancer
[171].
4.4.2. Genistein. Genistein (4 ,5,7-trihydroxyisoﬂavone), an
isoﬂavonoid found in soybeans, has both chemopreventive
and antiangiogenic activity. It suppresses carcinogenesis in
a variety of animal models of mammary and prostate
carcinoma following oral and parenteral administration
[172–174]. Multiple antitumor mechanisms of action have
been identiﬁed, including angiogenesis inhibition, induc-
tion of apoptosis, G2 cell cycle arrest, inhibition of c-fos
expression and NF-κB activation, modulation of sex steroid
receptors and growth factor signaling pathways [175–177].
Genistein inhibits angiogenesis by the following mecha-
nisms: inhibition of bFGF- and VEGF-driven endothelial cell
proliferation, migration, and tube formation; inhibition of
extracellular matrix degradation by suppression of bFGF-
induced endothelial production of plasminogen activator
(PA) and plasminogen activator inhibitor (PAI); and sup-
pression of receptor tyrosine kinase activity for VEGF, EGF,
and PDGF [178, 179].
The antiangiogenic activity of genistein was initially
detected in a study of healthy Japanese individuals who con-
sumed a traditional soy-rich Japanese diet [180]. Urine from
these subjects was collected, fractionated, and examined for
activity to inhibit bFGF-stimulated endothelial cell prolif-
eration. Of two fractions with antiendothelial activity, one
contained genistein, daidzein, and O-desmethylangolensin.
The impact of dietary soy intake was signiﬁcant. In men who
consumed a Japanese versus Western diet, urinary genistein
was7052nmol/daycomparedto184.4nmol/day,respectively
[181]. Soy intake has been shown to be inversely associated
with cancer risk. Historically, breast cancer incidence rates
have been 4 to 7 times higher among white women in the US
compared to in women in China or Japan. However, when
Asian women migrate to the US, their breast cancer risk rises
over several generations to reach that of US white women,
suggesting that modiﬁable factors, such as diet, rather than
genetics, are responsible for the international diﬀerences. A
study of over 73,000 women in China showed that daily
intake of soy products such as soy milk, tofu, and fresh
soybeans decreased premenopausal breast cancer risk [182].
Likewise, American women of Asian descent who consume
a traditional soy-based diet have a low incidence of breast8 Journal of Oncology
cancer [178, 183]. Early soy intake (>1.5 times per week)
duringchildhoodwasfoundtoreducelaterbreastcancerrisk
by 58% in a study of Asian women in California and Hawaii
[184]. Similarly, Japanese men in Hawaii who consume
a high soy diet have low mortality from prostate cancer,
althoughtheincidenceatautopsyofinsituprostateneoplasia
is similar to men in Western societies [185]. Based on
laboratory ﬁndings and epidemiological data, genistein and
a manufactured derivative known as genistein-concentrated
polysaccharide (GCP), are being evaluated in prevention
trials for prostate cancer [186].
Such clinical studies have helped dispel the theoretical
concernsthatsoyintakemayworsenbreastcancerorinteract
with tamoxifen treatment due to the fact that genistein is a
phytoestrogen.Infact,amongwomenwithbreastcancer,soy
food consumption has now been shown in numerous, large-
scale studies to be signiﬁcantly associated with decreased
risk of death and recurrence, regardless of estrogen receptor
s t a t u so rt a m o x i f e nu s e[ 187].
4.4.3. Resveratrol. Resveratrol (3,4 ,5-trihydroxystilbene) is
a natural phytoalexin and polyphenol found in more than
72 plant species, such as mulberries, peanuts, grapes, and
grape products, including red and rose wine. Fresh grape
skins contain 50–100μg resveratrol per g and yield a
concentration in Italian red wine of 1.5–3mg/L [188]. White
wine contains minimal levels of resveratrol. Resveratrol
inhibits angiogenesis in the chick CAM assay, suppresses
VEGF- and bFGF-induced corneal neovascularization (at 3-
4mg, equivalent to 3-4 glasses red wine/day), and inhibits
tumor vascularization in T241 ﬁbrosarcoma growing in
mice [189]. Resveratrol also inhibits chemically induced
mammary carcinogenesis, skin cancer tumorigenesis, and
tumor growth and metastasis in mice bearing Lewis lung
carcinoma [188, 189]. In mice with full thickness skin
wounds, resveratrol delays wound healing angiogenesis and
the time required for complete wound closure [190]. A
number of antiangiogenic mechanisms have been identiﬁed,
including suppression of capillary tube formation inhibition
of endothelial cell DNA synthesis and binding of VEGF to
human endothelial cells reduction of vascular cell adhesion
molecule-1 (VCAM-1) interference with phosphorylation of
endothelial mitogen-activated kinases; suppression of COX-
2 enzyme and inhibition of MMP-9 expression [189, 191–
193].
Redwineinparticularhasbeenrepeatedlyshowntohave
protective eﬀects in large population studies. The California
Men’s Health study of over 84,000 men demonstrated an
inverserelationshipbetweenredwineconsumptionandlung
cancerincidence. Notably, there was a 61% risk reduction for
men drinking at least one glass of red wine per day [194].
This protective beneﬁt for lung cancer with greater than one
glass per day was replicated in a Spanish population, using a
case-controlmethodologyinvolvinghospitalizedlungcancer
patients[195].Additionally,theHealthProfessionalsFollow-
upStudyidentiﬁedaprotectiveeﬀectforprostatecancerwith
a 36% risk reduction in men drinking 2–4 glasses of red wine
per week [196].
4.4.4. Lycopene. Lycopene, a type of natural pigment in the
carotenoid family, gives tomatoes and other fruits such as
watermelon and papayas their bright red color. Lycopene
is an angiogenesis inhibitor which suppresses signaling by
PDGFandPlateletActivationFactorinvitro[197].Inanimal
studies,lycopenesuppressesspontaneousmammarytumors,
hepatocarcinogenesis,coloniccryptfoci,prostatecancer,and
hepatoma metastases [198].
Two interventional studies have also demonstrated
potent biologic eﬀects of lycopene in the setting of malig-
nancy. In one study, 32 men who were recently diagnosed
with early-stage prostate cancer were instructed to eat one
meal per day incorporating commercially made tomato
sauce containing 30mg of lycopene for 3 weeks. They then
underwent curative prostatectomy; pathologic examination
of the resected tissue showed a 3-fold increase of lycopene
concentration in the prostate tissue, along with a slight
decrease in blood prostate-speciﬁc antigen (PSA) level [199].
In a separate study, 41 men with recurrent prostate cancer
were asked to consume a tomato-rich diet to achieve a mini-
mumlycopeneintakeof25mg/dayalongwith40g/dayofsoy
protein for a total of 8 weeks. While the study design made it
diﬃculttoseparatethedietaryeﬀectsoflycopenefromsoy,it
isnotablethatthemeanserumVEGFlevelsofallthesubjects
was reduced from 87 to 51ng/mL in a statistically signiﬁcant
way,andthat34%ofthemenexperiencedreducedPSAlevels
[200].
In the Health Professionals Follow-Up Study of over
51,000 men, the highest quintile of lycopene consumption
was found to have a 15% risk reduction for developing
prostatecancercomparedtomeninthelowestquintile[201].
The risk reduction was even greater if tomato sauce was
ingested; men consuming more than 2 servings/week had a
nearly 23% risk reduction compared to men consuming less
than 1 serving/month.
4.4.5. Omega-3 Polyunsaturated Fatty Acids (PUFAs).
Omega-3 fatty acids are unsaturated fatty acids that are
vital for normal metabolism but cannot be synthesized by
the human body. The best known sources of the long-
chain omega-3 fatty acids—docosahexaenoic acid (DHA)
and eicosapentaenoic (EPA)—are cold water oily ﬁsh
such as salmon, herring, mackerel, anchovies, sardines,
and trout. Both preclinical and epidemiological studies
suggest that omega-3 PUFAs are eﬀective cancer prevent-
ative agents. Omega-3 PUFAs inhibit angiogenesis by
downregulating angiopoietin-2 and may competitively
inhibit the bioconversion of omega-6 PUFA’s into their
angiogenesis-promoting derivatives such as prostaglandins
and arachidonic acid [202]. In contrast, omega-6 PUFAs,
present at high levels in sunﬂower oil, peanut oil, and corn
oils, have been shown in vitro to stimulate endothelial
migration and tube formation. Furthermore, omega-3
PUFAs have been shown to suppress Akt/m-TOR signaling
pathway [203]. In animal models, Omega-3 fatty acids have
been shown to suppress a variety of tumors and to prevent
osteolytic metastastic lesions in bone from breast cancer
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Intake of omega-3 PUFAs from seafood has been asso-
ciated with a decreased risk for certain cancers, including
pancreatic, colon, breast, and prostate cancer. In a case-
control study of 532 people diagnosed with pancreatic
adenocarcinoma, consumption of omega-3 fatty acid of
at least 0.85g/day was associated with a decreased risk of
pancreatic cancer; those with the highest intake had a 30%
risk reduction [205]. A meta-analysis of ﬁsh intake and
prostate cancer in case-control and cohort studies revealed
no association between ﬁsh consumption and prostate
cancer incidence, but showed a signiﬁcant 63% reduction in
prostate cancer mortality [206].
4.4.6. Glucosinolates, Isothiocyanates, and Indole-3-carbinol.
Cruciferous vegetables—which include cabbage, broccoli,
cauliﬂower, collard greens, mustard greens, radishes, Brussel
sprouts, bok choy, and kale—are rich in glucosinolates, a
mustard oil glycoside that imparts a spicy, bitter ﬂavor.
The enzyme myrosinase—stored in a separate compart-
ment of the plant cell and liberated when the plant is
crushed—converts glucosinolate to the bioactive molecules
isothiocyanate and indole-3-carbinol, both of which are
antiangiogenic. Sulforaphane, a type of isothiocyanate, acts
through inactivation of hypoxia inducible factor-1 alpha,
activation of FOXO transcription factors, and promotion
of endothelial cell apoptosis [207–209]. Indole-3-carbinol
inhibits endothelial cell proliferation, tube formation and
induces apoptosis [210, 211].
Epidemiological evidence suggests that regular dietary
intake of cruciferous vegetables may lower the risk of
developing several cancers. A major prospective dietary
study, the European Prospective Investigation into Cancer
and Nutrition (EPIC), followed the dietary habits and
health of 521,468 subjects in 10 European countries between
1991–2000 [212]. After an average followup of 8.7 years,
1,830 people were diagnosed with lung cancer. Regular
consumption of cauliﬂower and cabbage by current smokers
wasassociatedwitha23%reductionintheriskforsquamous
cells carcinoma of the lung. The study also found an almost
50% reduced risk of cancer of the upper digestive tract (oral
cavity, pharynx, larynx, and esophagus) among people who
ate the most cauliﬂower and cabbage (34g/day) compared
with those who ate the least (3g/day) [213].
Another large prospective study of more than 35,000
women living in Iowa and followed for 20 years found
a 18% reduced risk for non-Hodgkin’s lymphoma (NHL)
among women who had the highest consumption of cru-
ciferous vegetables; in particular, consumption of at least
4 servings/month or broccoli was associated with a 28%
risk reduction for non-Hodgkin’s lymphoma [214]. In
separate study of nearly 67,000 women in the Nurses’ Health
Study, more frequent dietary intake of broccoli (at least 2
servings/week) was associated with a 33% risk reduction for
ovarian cancer [215].
4.4.7. Flavonoids. Flavonoids are a family of polyphenols
that serve as important plant pigments. Their natural roles
may include acting as photoprotectants, antimicrobials,
deterrents against herbivores, as well as attractants to polli-
nators and seed dispersant animals. They are subcategorized
by chemical structure into ﬂavones, ﬂavonols (such as
quercetin), anthocyanidins, proanthocyanidins, ellagic acid,
ellagitannins, and isoﬂavones (such as genistein mentioned
earlier), among others. In contrast, the term ﬂavanol speciﬁ-
cally refers to the catechins, mentioned earlier.
Flavonoids in fruits and vegetables include quercetin,
anthocyanidins, proanthocyanidins, ellagitannins, among
others. Flavonoids are antiangiogenic through a variety of
mechanisms; they inhibit VEGF expression, inhibit endothe-
lial cell migration, and decrease matrix metalloproteinases
MMP-2 and MMP-9 [216–220]. The U.S. Department of
Agriculture identiﬁes spinach, onions, parsley, beets, and
thyme among high ﬂavonoid-containing vegetables and
herbs [221]. Fresh salad greens such as lettuce, chicory,
arugula, and red lettuce are also rich in polyphenolic
ﬂavonoids [222].
Quercetin. Quercetinisaﬂavonoidfoundinnumeroustypes
of fruits and vegetables. Its antiangiogenic properties include
inhibition of MMP-2 and MMP-9 secretion from tumor
cells and inhibition of endothelial cell proliferation and
migration [219]. For example, quercetin has been shown to
reduce in vitro tube formation of VEGF-stimulated human
umbilical vein endothelial cells (HUVECs) grown on a 3-
dimensional matrix by as much as 40% [220]. With regards
to epidemiologic data, a large prospective study of 41,000
women living in Iowa between the ages of 55 and 69 found
a number of ﬂavonoid-containing leafy greens, which are
abundant in quercetin, was associated with a signiﬁcant risk
reductionforlungcancer[223].Womenwhoreportedeating
more than six servings of leafy greens per week were nearly
half as likely to develop lung cancer during the four-year
follow-up period, when compared to women who ate the
least greens. This beneﬁt extended to both smokers and
nonsmokers alike.
One of the richest sources of dietary ﬂavonoids is red
onion, which has particularly high levels of quercetin. Case
control studies from Italian and Swiss populations have
shown that moderate (1–7 servings/week) to high frequency
(>7 servings/week) of onion consumption protects against
a variety of cancer including colorectal, prostate, ovarian,
and laryngeal cancers [224]. For example, there was a nearly
73% risk reduction for ovarian cancer in the population
when comparing those who frequently consumed onion
(>7 servings/week) compared to those with less frequent
consumption (<1 serving/week). Similarly, there was an
88% risk reduction for esophageal cancer in the group with
highest versus lowest onion intake. In a separate Dutch
cohort study, consumption of at least half an onion/day was
associated with 50% risk reduction in gastric cancer [225].
Finally, researchers using data from the large-scale EPIC
study showed that high onion consumption was associated
with a 21% risk reduction for ovarian cancer [226].
Anthocyanins. Anthocyanins are pigments that are present
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They exhibit a purple color at neutral pH, red in acidic, and
blue in alkaline conditions. Anthocyanins are end-products
of the ﬂavonoid pathway, while anthocyanidins are their
aglycone precursors. Their natural function may be to attract
pollinators and animals to eat the fruit or plant and disperse
their seeds.
They have been shown to inhibit angiogenesis and tumor
growth in experimental animals injected subcutaneously
with N-nitrosomethylbenzylamine (NMBA), an esophageal
carcinogen [227]. Rats that were fed an anthocyanin-rich
freeze-friedextract(5%indiet)obtainedfromblackraspber-
ries (BRB), blackberries, or strawberries showed a reduced
number of esophageal tumors as compared to controls
–41% less by BRB, 46% less by blackberries, and 24%
less by strawberries [228]. In another study of esophageal
papillomas in rats, animals fed BRB had fewer papillomas
that were of smaller volume, with reduced cell proliferation
and suppression of VEGF and HIF-1alpha expression seen
by immunohistochemistry as compared to the non-BRB
treated mice [229, 230]. DNA microarray studies of rat
esophageal carcinogenesis have shown that dietary black
raspberries modulate the expression of genes associated with
angiogenesis, including the cyclooxygenase and lipoxygenase
pathways of arachadonic acid metabolism, as well as MMP-
10 expression; CD34 staining as a marker for microvessel
density was also found to be signiﬁcantly reduced in the
BRB diet animals [228, 229]. Berries are also rich in other
natural polyphenols such as ellagic acid, which contributes
to bioactivity.
An extract from black raspberries has been studied in
human subjects diagnosed clinically with oral intraepithelial
neoplasia. BRB 10% was applied in a gel form to the oral
mucosa four times daily. After 6 weeks, there was reduced
histological grade of dysplastic lesions in 50% of treated
subjects, and reduced levels of COX-2 and iNOS in the
lesions [231].
Proanthocyanidins. Proanthocyanidins are a type of ta-
nnin—large polymeric chains of ﬂavonoids—found in many
plants and fruits, notably cacao, cinnamon, cranberry,
apples, grapes, black current, chokeberry, and persimmon.
Proanthocyanidins are thought to be the major source of
ﬂavonoids ingested in the Western diet [232]. Historically
tannins from wood bark were used as tanning agents to turn
animal hide into leather due to their ability to precipitate
proteins. They are also responsible for the astringent taste of
certain foods and beverages [233]. Among their natural roles
is protection against predation [234]. Anthocyanins and
proanthocyanidins share steps in the ﬂavonoid biosynthetic
pathway. Speciﬁcally, proanthocyanidins are generated from
the polymerization of ﬂavonoid monomers, which are
products of a branch pathway of anthocyanin biosynthesis.
Proanthocyanidins constitute 60% of the polyphenol
content in cacao, the source of chocolate [235]. It is in
the yeast-based fermentation of the raw cacao bean where
the characteristic ﬂavor precursors develop and polyphenols
complex into procyanidin polymers with a core structure
of (–)-epicatechin, similar to green tea [236]. Pentameric
and octameric procyanidins isolated from cacao beans have
been shown to inhibit the growth of cultured human
aortic endothelial cells and human dermal microvascular
endothelial cells (HDMECs) following angiogenic stimu-
lation with low-level H2O2 [237]. The cacao pentameric
fraction downregulates the expression of ErbB2 tyrosine
kinase. Cocoa powder extract inhibits TNF-alpha-induced
VEGF secretion in vitro. When JB6 mouse epidermal
cells were pretreated with a polyphenol-rich cocoa powder
extract, then exposed to TNF-alpha, there was a dose-
dependent inhibition of TNF-alpha-induced VEGF expres-
sion compared to untreated controls [238]. At the highest
but noncytotoxic concentration of cacao extract, VEGF
expression was reduced more than twofold compared to
controls.
There is evidence that cacao consumption can aﬀect
human vasculature and health. After ingestion, cacao
ﬂavonoids are stable in the gastric environment and can
be detected in human plasma [239]. In studies of human
volunteers, angiotensin-converting enzyme (ACE) activity is
inhibited by 18% only three hours after a single intake of
75grams of dark (72% cocoa) chocolate [240]. In a study
of 4,849 individuals in Italy, those who ate one 20 gram
serving of dark chocolate every 3 days had serum C-reactive
protein (CRP) signiﬁcantly lower than those who did not
[241].Notably,theKunaIndianslivingontheSanBlasIsland
of Panama—who have a ten-fold higher dietary intake of
cacao compared to Panamanian mainlanders—have lower
blood pressure, live longer, and have lower incidence of
cancercomparedtomainlanders[242].Consistentwiththeir
cacao consumption, the Kuna have 6-times higher urinary
excretionofcacaoprocyanidinmetabolitesthanmainlanders
[243].
Procyanidins are also found in cinnamon, which have
been found to inhibit angiogenesis and tumor growth.
Cinnamon extract inhibits VEGF receptor-2 on endothelial
cells and suppresses endothelial cell proliferation, migration,
and tube formation in vitro [244]. A water-soluble extract
from dried cinnamon bark, orally administered every day
or every other day for 20 days to mice bearing experi-
mental melanomas suppresses melanoma growth [245]. The
cinnamon extract suppressed tumor microvessel density,
and as shown by quantitative RT-PCR, the expression of
angiogenic factors VEGF, FGF, and TGF-β as well as COX-2
and HIF-1alpha, which promote angiogenesis. In addition,
the cinnamon extract suppresses melanoma metastasis as
measured by the size and weight of the spleen and draining
lymph nodes of mice bearing melanoma in vivo [245].
Many edible berries also contain proanthocyanidins,
including the American cranberry, black currants, and
grapes. Chokeberries, named because of their extreme
astringency, contain among the highest levels of proan-
thocyanidins detected [246]. Mixtures of berry extracts
inhibit tube formation of endothelial cells in Matrigel
[247]. Extracts from blueberries, bilberries, raspberries, and
strawberries suppress VEGF expression by immortalized
human keratinocytes (HaCaT cells) in vitro and this VEGF
inhibition appears to be independent of the antioxidant
property of the extracts [247]. Experimental liver cancer in
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number and size by an extract from black currants added
to the animal’s diet (equivalent to 500mg/kg body weight)
[248]. Procyanidins in cranberries may have multiple health
beneﬁts including both chemopreventive properties as well
as maintaining bladder health due to inhibiting E. Coli
adherence to uroepithelium [249]. A cranberry extract tested
onDU145humanprostatecancercellssigniﬁcantlyinhibited
expression of MMP-2 and MMP-9 and increased expression
ofTIMP-2invitro,consistentwithmechanismsthatsuppress
angiogenesis [250]. Cranberry juice, given as a 20% solution,
reduces the incidence of azoxymethane-induced colonic
aberrantcryptsinratsby77%versusdrinking watercontrols
when supplemented for three weeks before and ten weeks
after carcinogen exposure [251].
Both apples and apple juice are rich sources of procyani-
dins in addition to other polyphenols previously described
such as quercetin and catechins. Based on the USDA
Continuing Survey of Food Intakes by Individuals (CSFII),
apples are a major source of proanthocyanidins in the
U.S. diet [232]. In a recent study, scientists examined the
speciﬁc chemopreventive properties of a polyphenol extract
ofapplejuice.AppleprocyanidinswerefoundtoinhibitCox-
1[ 252]. Several studies have shown that cloudy apple juices,
such as apple cider, contain much higher concentrations of
procyanidins than clear apple juices. Speciﬁcally, one study
determinedthatthesuspendedparticlesincloudyapplejuice
contain up to 60% of apple procyanidins in the juice.
Epidemiologicalstudieshaveprovidedaccumulatingevi-
dence that apples have cancer-preventive properties, particu-
larlyagainstlungandcolorectalcancers.IntheNursesHealth
Study involving 77,000 women, a statistically signiﬁcant 37%
risk reduction for lung cancer was observed among women
for increases of 1 serving per day of apples or pears [253].
Similar results were obtained from a Finnish cohort study
involving 10,000 men and women [254]. The results of
a case-control study conducted in Hawaii with 528 lung
cancer cases and 528 controls found a statistically signiﬁcant
decrease in lung cancer risk with increased consumption of
apples [255]. An analysis of case-control studies conducted
in Italy found that people who consumed at least one apple
per day had a signiﬁcantly reduced risk of colorectal cancer
and cancers of the oral cavity, larynx, breast, and ovary
relative to those who ate less than an apple a day [256]. In a
prospective cohort of 35,159 Iowa women aged 55–69 years,
intake of apple juice or cider was associated with lower risk
of developing non-Hodgkin’s lymphoma [214].
Ellagitannins. Ellagitannins are glycosides of the ﬂavonoid
ellagic acid and fall under the category of hydrolyzable
tannins. They can be found in numerous types of fruits
and nuts including pomegranate, strawberries, blackberries,
raspberries, muscadine grapes, walnuts, and pecans [257].
Upon consumption, ellagitannins are hydrolyzed to ellagic
acid which is antiangiogenic. Colonic microbiota further
convert ellagic acid to urolithin A which is also bioactive
[258].
All parts of the pomegranate contain high levels of
ellagitannins, of which the primary type is punicalagin.
Bioactive polyphenols are found not only in the edible aril
(pulp and seed) which is popularly consumed, but also
concentrated in the peel of the fruit, which is not usually
consumed but may be part of the juice extraction by some
processors. Indeed, polyphenol extraction increases 6.5-fold
when the whole fruit is processed compared to juice from
arils alone [259]. Ellagitannins have been shown to inhibit
the growth of prostate cancer in both in vitro and in vivo
laboratory experiments, and studies have suggested that
the compound’s antiangiogenic properties play a role in
this inhibition. Interestingly, pure pomegranate juice has
been found to be more potent than its separated individual
polyphenol components, likely due to synergistic eﬀects
[260]. Eﬀects of pomegranate extract (POMx)—derived
fromtheskinandseedsofthepomegranatefruit—havebeen
shown on endothelial cells (HUVECs) and human prostate
cancer cells (LNCaP line) in vitro [261]. Pomegranate extract
inhibited the proliferation of both cell types and suppressed
the secretion of VEGF and HIF-1alpha. Mice implanted with
human prostate tumors derived from the LAPC4 tumor line
wereadministeredthehumanequivalentof1.7cups(8oz)of
pomegranate juice per day. Pomegranate juice signiﬁcantly
decreased tumor microvessel density, as well as tumor size,
compared to the control animals [261]. Pomegranate juice,
when given as a 20% solution, reduces the incidence of
azoxymethane-induced colonic aberrant crypts in rats [251].
In a study of men with recurrent prostate cancer who drank
1 cup of pomegranate juice per day, their prostate-speciﬁc
antigen (PSA) doubling time was extended from 15 to 54
months [262].
4.4.8. Menaquinone. A form of vitamin K, menaquinone
(vitaminK2),foundincertainfoodsourcesisantiangiogenic
and associated with a reduced risk for developing several
forms of cancer. Menaquinone is distinct from the phyl-
loquinone (Vitamin K1) present in dark leafy vegetables.
Instead, menaquinone is a fat—soluble vitamin formed
naturally by bacteria in fermented dairy products, including
cheese and yogurt, in fermented soy such as natto, and
also present in dark meat. Certain cheeses, such as Dutch
Gouda, Swiss Emmental, and Norwegian Jarlsberg, have
particularly high concentrations of menaquinone. In labora-
tory studies, menaquinones suppress angiogenesis, enhance
tumor apoptosis, and inhibit the proliferation of cancer cells
[263].
A subpopulation of the European Prospective Inves-
tigation into Cancer and Nutrition (EPIC) study, called
the Heidelberg cohort, followed the diet and health status
of more than 24,300 participants for at least ten years,
starting in 1994. The participants answered detailed ques-
tionnaires at regular intervals about their diet and general
health. During the follow-up period, 1,775 cancer cases
were diagnosed, of which 458 were fatal. Among the
foods documented, participants who consumed the most
cheese (at least 41g/day) had a signiﬁcantly reduced risk
of dying from cancer compared with those who consumed
the least (less than 14g/day) [264]. Cheese consumption
contributed to about 45% of total menaquinone intake. In
terms of speciﬁc cancers, higher consumption food con-
taining menaquinone was associated with signiﬁcantly lower12 Journal of Oncology
incidences of lung cancer and prostate cancer. Participants
with the highest levels of menaquinone in their diets had
a 62% reduced risk of lung cancer compared with those
with the least, and a similar reduced risk of dying from lung
cancer.
Prospective clinical studies of vitamin K2 have shown
chemopreventive activity in patients. In a study of 40 women
in Osaka diagnosed with viral liver cirrhosis, individuals
were assigned randomly to an intervention or control group.
During more than 7 years of followup, the cumulative pro-
portion of people who developed hepatocellular carcinoma
(HCC) was signiﬁcantly smaller in the group that received
vitaminK2(45mg/day)[265].VitaminK2decreasedtherisk
ofHCCto20%comparedtothatofthecontrolgroup.Onan
annual incidence basis, HCC developed in only 1.6% in the
treatment group compared with 8.8% in the control group
and 7.9% in the general cirrhotic population.
4.4.9. Curcumin. Curcumin (diferuloylmethane), a ﬂavon-
oid derived from the plant Curcuma longa,i sp r e s e n t
in tumeric spice. It has chemopreventive and antiangio-
genic activity and inhibits carcinogenesis in skin, stomach,
intestines, and liver. Dietary ingestion of curcumin has been
shown to prevent the formation of colon polyps, suppress
proliferation of colon cancer and prostate cancer cells,
and decrease intratumoral microvessel density [266–268].
Studiesofendothelialcellsexposedinvitrotocurcuminshow
induction of apoptosis; downregulation of gene transcripts
for VEGF, bFGF, and MMP-2; COX-2 inhibition; upregu-
lation of TIMP; disruption of vascular tube formation; and
inhibition of endothelial cell motility by interfering with the
Ras-mediated c-Jun N-terminal kinase (JNK) pathway [269–
273].
APhaseIpreventiontrialofcurcumin(500–800mg/day)
showed histological improvement of lesions in patients
with various malignant and premalignant lesions, including
recently resected bladder cancer, oral leukoplakia, intestinal
metaplasia, CIN, and Bowen’s disease [274]. In a Phase II
study, dietary curcumin was given for 30 days to 44 subjects
with aberrant crypt foci (ACF), a premalignant marker for
colorectal cancer. Those who consumed 4g/day of curcumin
had a 40% reduction in the number of rectal ACF lesions
[275].
4.4.10. Beta-cryptoxanthin. Beta-cryptoxanthin is a natural
carotenoid pigment present in brightly colored orange,
red, or yellow foods. Structurally it is related to beta-
carotene, and is ultimately metabolized to vitamin A in
the body and can be found circulating in the blood after
consuming carotenoid-rich foods. Vitamin A and retinoic
acid analogs are antiangiogenic and synthetic derivatives
havebeeninvestigatedaschemopreventiveagents[276–280].
Papaya is a rich source of carotenoids, with the
same lycopene content as tomatoes, but twice the beta-
cryptoxanthin content. Studies in tropical populations have
shown that increased daily consumption of papayas results
in higher levels of beta-cryptoxanthin in the blood [281].
Consumption of such beta-cryptoxanthin-rich foods may
reduce cancer rates in high-risk populations. For example,
higher papaya consumption has been shown to be inversely
associated with the risk of developing high-grade cervical
lesions. A nested case control study involving a population
of HPV-positive women in Brazil showed that consuming
one or more servings of papaya per week cut the risk of
developing a high grade cervical lesion by 81% [282].
Other studies have shown a risk reduction with the
consumption of papaya and carotenoid-rich fruits for other
cancers, including lung and gall bladder cancers [283, 284].
In the Singapore Chinese Health Study, 63,257 Chinese
men and women ages 45–74 participated in a prospective
study of diet and cancer [284]. Using a food composition
database, an estimate of their carotenoid intake, including
beta-cryptoxanthin was quantiﬁed. In the ﬁrst 8 years of
follow-up, 482 lung cancer cases occurred in the cohort. A
high level of dietary beta-cryptoxanthin was associated with
reduced risk of lung cancer. Comparing the highest to lowest
quartile, there was a 27% risk reduction among all subjects,
and a 37% risk reduction among current smokers.
In a study of women, diet, and breast cancer risk,
403 breast cancer cases and 602 controls from the Nurses’
Health Study were examined for high breast densities,
a strong predictor for breast cancer risk [285]. Overall,
circulating total carotenoids were inversely associated with
breast cancer risk. Among women in the highest tertile of
mammographic density, total carotenoids were associated
with a 50% reduction in breast cancer risk.
4.4.11. Other Novel Dietary Inhibitors. We have identiﬁed
antiangiogenic activity in a number of other dietary-
derivedchemopreventivemolecules.Theseincludebrassinin,
a phytoalexin found in Chinese cabbage; the citrus-derived
bioﬂavonoids hesperidin and naringenin; ellagic acid from
berries, pomegranate, and grapes; silymarin from milk
thistle and artichoke; and the organosulfur allyl disulﬁde
derived from garlic [286–291]. Further studies are underway
to deﬁne their molecular targets in angiogenesis, their
optimal biological doses, and eﬃcacy in inhibiting tumor
vascularity.
The diverse natural sources of these and other antian-
giogenic chemopreventive molecules raise the possibility of
designing scientiﬁc diets for patients at high risk for cancer,
or for those with known disease to chronically suppress
angiogenesis and tumorigenesis.
5. Conclusion andFutureDirections
Angiogenesis is a critical, rate-limiting step in the devel-
opment of all known cancers, and its inhibition suppresses
tumor growth, progression, and metastases. Antiangiogenic
therapy represents a new approach to the early intervention
and prevention of malignant disease. During the next two
decades, the total yearly number of newly diagnosed cases
of cancer is projected to rise from 12.4 million new cases
per year in 2008 to 26.4 million in 2030, and the number of
annual deaths is projected to increase 170%, to 17 million
[292, 293]. According to the World Health OrganizationJournal of Oncology 13
and International Agency for Research on Cancer, cancer
is the leading cause of death worldwide as of 2010 [293].
The implementation of eﬀective chemoprevention strategies
based on angiogenesis inhibition attained through dietary
sources may decrease these numbers in a cost-eﬀective
and quality of life enhancing manner. Dietary eﬀects are
already thought to underlie many of the large international
diﬀerences in incidence seen for most cancers [294]. Indeed,
nutritional factors have been estimated to contribute to 20–
60% of cancers worldwide and to approximately one-third of
deaths from cancer in Western countries [295].
The identiﬁcation of dietary sources of antiangiogenic
molecules has been aided tremendously through observa-
tional epidemiologic studies, which have the ability to iden-
tify speciﬁc foods associated with reduced cancer risk. These
studies generally fall under the categories of prospective
cohort and retrospective case-control studies, and more of
both of these types of studies will be necessary to identify
additional sources of antiangiogenic compounds and to
help conﬁrm the chemopreventive properties of previously
identiﬁed foods and their constituent bioactive molecules.
The dietary prospective cohort study allows thorough
assessment of dietary exposures with a reduced risk of recall
bias as patients are initially cancer-free when enrolled. As
study participants are followed into the future and observed
for the development of cancer and other cancer-related
endpoints, investigators can identify speciﬁc foods present in
participants’ diets that are associated with cancer risk reduc-
tion. With the evolving understanding of the underlying
molecular basis of various naturally antiangiogenic foods, an
important consideration for future cancer prevention cohort
studies will be to ensure accurate assessment of participants’
dietary intake of bioactive compounds. This will include
not only comprehensively querying participants about all
potential dietary sources of the bioactive compounds of
interest, but also obtaining more detailed information about
the preparation of foods, as this can signiﬁcantly impact the
amount of antiangiogenic molecules obtained through diet.
Furthermore, the subtypes of foods consumed, such as the
speciﬁc variety of apple or tomato eaten by a participant,
and the way the food is processed or cooked prior to
consumption, can strongly aﬀect the amount of consumed
bioactive molecules and would be important information
to collect. Thus, while the food frequency questionnaires
(FFQs) used in past cohort studies have attempted to
quantify the intake of various foods, future studies focused
on antiangiogenesis may be able to make a more detailed
and accurate assessment of this particular aspect of dietary
intake.
Case-control studies can also be valuable as a method
for expediently identifying promising dietary exposures
without the need for the long timeframes and massive study
populationsthattypicallycharacterizedietarycohortstudies.
While case-control studies are nearly always vulnerable to
recall bias on the part of the cancer patients who compose
the case populations, they are a valuable starting point in
identifyingpromisingrisk-reducingfoodsthatcanbefurther
explored through prospective and, more recently, interven-
tional dietary studies. The key to these studies will be the
useofwell-designeddietarysurveyinstrumentsandmethods
to allow data capture on short time horizons that can
accurately gauge the intake of antiangiogenic and chemopre-
ventive biomolecules. Finally, interventional dietary studies
are a particularly promising methodology with which to
conﬁrm the antiangiogenic and chemopreventive properties
of speciﬁc foods and bioactive molecules. In particular,
recently diagnosed cancer patients or those with pre-invasive
angiogenesis-dependent lesions such as colonic adenomas,
prostatic intraepithelial neoplasia, cervical intraepithelial
neoplasia, and actinic keratoses could potentially show
signiﬁcant beneﬁt from short-term antiangiogenic dietary
interventions with regards to progression, metastasis, or
recurrence of their lesions [167]. Investigators with access
to serum or biopsy samples could also follow changes
to angiogenesis biomarkers, tumor biomarkers, or tumor
characteristics [262, 296]. Because of their experimental
nature, randomized interventional dietary studies have the
potential to become a valuable method for validating the
antiangiogenic nature of bioactive molecules and foods.
The United States Department of Agriculture’s update to
its longstanding Food Pyramid dietary recommendations—
namely, its replacement with the new MyPlate initiative that
pushes for an increase in the amount of whole fruits and
vegetables consumed at each meal—does appear to indi-
rectly promote increased consumption of certain foods that
contain natural sources of antiangiogenic molecules [297].
For example, speciﬁc recommendations of the initiative
include glucosinolate-rich cruciferous vegetables, lycopene-
containing tomatoes, resveratrol-bearing grape products,
andbeta-cryptoxanthin-abundantorangeandyellowvegeta-
bles.
Data and conclusions from rigorous dietary cancer
prevention studies should be implemented into public
health policy. Optimal health outcomes result not just from
high quality medical care, but also from diet and lifestyle
patterns that can intercept disease at the earliest microscopic
stages. Investments in cancer prevention, guided by the
biological principles of antiangiogenic therapy, will expand
on the substantial clinical applications already established
by the biopharmaceutical industry. Cancer prevention using
antiangiogenic factors present in widely available foods
further oﬀers an egalitarian strategy for large populations
in societies that increasingly recognize the value of health-
promoting dietary choices. Many dietary sources of angio-
genesis inhibitors are common ingredients in the world’s
most popular culinary traditions (i.e., Asian, Mediter-
ranean, etc.). We propose that an antiangiogenic diet is
a practical and cost-eﬀective method to reduce the risk
of cancer and other diseases and to enhance quality of
life.
In summary, tumor angiogenesis is a critical target for
cancer prevention. Natural antiangiogenic molecules are
present in numerous dietary sources and represent a wide
spectrum of mechanisms that can suppress the growth of
microscopic tumors. The control of blood vessel growth
through dietary antiangiogenesis promises toredeﬁne cancer
as a disease that can be suppressed throughout an individ-
ual’s lifetime, from infancy through adulthood.14 Journal of Oncology
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